Leerink Partnrs Brokers Reduce Earnings Estimates for OmniAb

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of OmniAb in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.64) per share for the year, down from their previous estimate of ($0.63). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. During the same quarter in the previous year, the company posted ($0.14) EPS.

Several other equities analysts also recently issued reports on OABI. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research report on Wednesday. Benchmark lowered their target price on OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday.

OmniAb Stock Performance

Shares of OABI opened at $2.53 on Friday. The stock has a fifty day moving average price of $3.34 and a two-hundred day moving average price of $3.77. OmniAb has a 52-week low of $2.23 and a 52-week high of $5.63. The company has a market cap of $357.28 million, a price-to-earnings ratio of -4.08 and a beta of -0.14.

Insider Buying and Selling

In related news, Director John L. Higgins acquired 125,750 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of $2.35 per share, with a total value of $295,512.50. Following the completion of the purchase, the director now directly owns 2,762,887 shares in the company, valued at approximately $6,492,784.45. This trade represents a 4.77 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kurt A. Gustafson sold 7,255 shares of OmniAb stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total value of $26,625.85. Following the transaction, the chief financial officer now owns 206,211 shares in the company, valued at approximately $756,794.37. This represents a 3.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,260 shares of company stock valued at $376,601 over the last three months. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in OmniAb by 3.3% during the fourth quarter. Invesco Ltd. now owns 93,653 shares of the company’s stock worth $332,000 after acquiring an additional 2,997 shares in the last quarter. Connors Investor Services Inc. lifted its holdings in OmniAb by 18.4% during the fourth quarter. Connors Investor Services Inc. now owns 29,611 shares of the company’s stock worth $105,000 after acquiring an additional 4,611 shares in the last quarter. SG Americas Securities LLC lifted its holdings in OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock worth $144,000 after acquiring an additional 5,751 shares in the last quarter. Sherbrooke Park Advisers LLC lifted its holdings in OmniAb by 53.5% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after acquiring an additional 6,001 shares in the last quarter. Finally, Isthmus Partners LLC lifted its holdings in OmniAb by 1.6% during the fourth quarter. Isthmus Partners LLC now owns 453,135 shares of the company’s stock worth $1,604,000 after acquiring an additional 7,001 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.